REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID ...

CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.

Nextcure ( ($NXTC) ) has released its Q3 earnings. Here is a breakdown of the information Nextcure presented to its investors. NextCure, Inc. is a ...

Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024. The decrease of $2.6 ...

Researchers from Nobel Laureate David Baker's lab at the University of Washington have successfully used AI to design ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...